BriaCell Therapeutics Announces Closing of $13.8 million Public Offering
BriaCell Therapeutics, a clinical-stage biotech company focused on cancer immunotherapy, has successfully closed its public offering raising $13.8 million in gross proceeds. The offering consisted of 3,066,666 units, including 399,999 units from the full exercise of the underwriter's option.
Each unit, priced at $4.50, includes one common share (or pre-funded warrant) and one warrant. The warrants, trading under symbol BCTXZ on Nasdaq, allow holders to purchase one common share at $5.25 and expire in five years.
- ThinkEquity served as the sole book-running manager
- Offering was registered with SEC (Form S-1 File No. 333-286670)
- Funds will support working capital, corporate purposes, and business objectives
The transaction utilized the TSX Company Manual Section 602.1 exemption for eligible Nasdaq-interlisted issuers. The offering was conducted through a prospectus available via ThinkEquity and the SEC website.
BriaCell Therapeutics, una società biotecnologica in fase clinica specializzata nell'immunoterapia oncologica, ha completato con successo la sua offerta pubblica raccogliendo 13,8 milioni di dollari lordi. L'offerta ha incluso 3.066.666 unità, di cui 399.999 derivanti dall'esercizio completo dell'opzione dell'intermediario.
Ogni unità, al prezzo di 4,50 dollari, comprende una azione ordinaria (o un warrant pre-finanziato) e un warrant. I warrant, quotati con il simbolo BCTXZ su Nasdaq, consentono ai possessori di acquistare un'azione ordinaria a 5,25 dollari e scadono dopo cinque anni.
- ThinkEquity ha agito come unico gestore principale
- L'offerta è stata registrata presso la SEC (Modulo S-1, File No. 333-286670)
- I fondi saranno utilizzati per capitale circolante, scopi aziendali e obiettivi commerciali
La transazione ha sfruttato l'esenzione della Sezione 602.1 del Manuale della TSX per emittenti idonei quotati su Nasdaq. L'offerta è stata effettuata tramite un prospetto disponibile su ThinkEquity e sul sito della SEC.
BriaCell Therapeutics, una empresa biotecnológica en etapa clínica enfocada en inmunoterapia contra el cáncer, ha cerrado con éxito su oferta pública recaudando 13,8 millones de dólares en ingresos brutos. La oferta consistió en 3.066.666 unidades, incluyendo 399.999 unidades por el ejercicio completo de la opción del suscriptor.
Cada unidad, con un precio de 4,50 dólares, incluye una acción común (o warrant prefinanciado) y un warrant. Los warrants, que cotizan bajo el símbolo BCTXZ en Nasdaq, permiten a los tenedores comprar una acción común a 5,25 dólares y vencen en cinco años.
- ThinkEquity actuó como único administrador principal
- La oferta fue registrada ante la SEC (Formulario S-1, Archivo No. 333-286670)
- Los fondos se destinarán a capital de trabajo, propósitos corporativos y objetivos comerciales
La transacción utilizó la exención de la Sección 602.1 del Manual de la TSX para emisores elegibles interlistados en Nasdaq. La oferta se realizó mediante un prospecto disponible a través de ThinkEquity y el sitio web de la SEC.
BriaCell Therapeutics는 암 면역치료에 주력하는 임상 단계의 바이오테크 기업으로, 공모를 성공적으로 마쳐 1,380만 달러의 총 수익을 확보했습니다. 이번 공모는 3,066,666 단위로 구성되었으며, 이 중 399,999 단위는 인수인의 옵션 전면 행사에 따른 것입니다.
각 단위는 4.50달러에 책정되었으며, 보통주 1주(또는 선행 인수권)와 워런트 1주를 포함합니다. 워런트는 나스닥에서 BCTXZ 심볼로 거래되며, 보유자는 5.25달러에 보통주 1주를 구매할 수 있고 만료 기한은 5년입니다.
- ThinkEquity가 단독 주관사로 참여
- 공모는 SEC에 등록됨(서류 번호 S-1, 파일 번호 333-286670)
- 자금은 운전자본, 기업 목적 및 사업 목표에 사용될 예정
이번 거래는 TSX 회사 매뉴얼 섹션 602.1의 나스닥 상장 적격 기업 면제를 활용했습니다. 공모는 ThinkEquity와 SEC 웹사이트를 통해 제공된 설명서를 통해 진행되었습니다.
BriaCell Therapeutics, une société biotechnologique en phase clinique spécialisée dans l'immunothérapie contre le cancer, a clôturé avec succès son offre publique en levant 13,8 millions de dollars de produit brut. L'offre comprenait 3 066 666 unités, dont 399 999 unités issues de l'exercice complet de l'option du souscripteur.
Chaque unité, au prix de 4,50 dollars, comprend une action ordinaire (ou un warrant préfinancé) et un warrant. Les warrants, cotés sous le symbole BCTXZ sur Nasdaq, permettent à leurs détenteurs d'acheter une action ordinaire à 5,25 dollars et expirent dans cinq ans.
- ThinkEquity a agi en tant que gestionnaire unique
- L'offre a été enregistrée auprès de la SEC (Formulaire S-1, dossier n° 333-286670)
- Les fonds serviront au fonds de roulement, aux fins corporatives et aux objectifs commerciaux
La transaction a utilisé l'exemption de la section 602.1 du manuel de la TSX pour les émetteurs admissibles cotés sur Nasdaq. L'offre a été réalisée via un prospectus disponible auprès de ThinkEquity et sur le site de la SEC.
BriaCell Therapeutics, ein biotechnologisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Krebsimmuntherapie, hat seine öffentliche Angebotsrunde erfolgreich abgeschlossen und dabei 13,8 Millionen US-Dollar Bruttoerlös erzielt. Das Angebot umfasste 3.066.666 Einheiten, darunter 399.999 Einheiten aus der vollständigen Ausübung der Option des Underwriters.
Jede Einheit, zum Preis von 4,50 US-Dollar, beinhaltet eine Stammaktie (oder einen vorfinanzierten Warrant) sowie einen Warrant. Die Warrants, die unter dem Symbol BCTXZ an der Nasdaq gehandelt werden, berechtigen die Inhaber zum Kauf einer Stammaktie zu 5,25 US-Dollar und verfallen nach fünf Jahren.
- ThinkEquity fungierte als alleiniger Bookrunner
- Das Angebot wurde bei der SEC registriert (Formular S-1, Aktenzeichen 333-286670)
- Die Mittel werden für das Betriebskapital, Unternehmenszwecke und Geschäftsziele verwendet
Die Transaktion nutzte die Ausnahme gemäß Abschnitt 602.1 des TSX-Unternehmenshandbuchs für berechtigte Nasdaq-interlistete Emittenten. Das Angebot wurde über einen Prospekt durchgeführt, der über ThinkEquity und die SEC-Website verfügbar ist.
- Successfully raised $13.8 million in gross proceeds through public offering
- Full exercise of underwriter's option to purchase additional units, showing strong demand
- 5-year warrant term provides long-term optionality for investors
- Dual-listed on major exchanges (Nasdaq and TSX) providing better trading liquidity
- Dilutive share offering impacting existing shareholders
- Offering price of $4.50 per unit indicates potential discount to market price
- Company requires additional capital for working capital and operations
- Pre-funded warrants and additional warrants could lead to future dilution if exercised
Insights
BriaCell raises $13.8M through unit offering with warrants, providing funding for operations while creating shareholder dilution.
BriaCell has completed its previously announced offering, raising
This capital raise represents a significant financial event for the clinical-stage biotechnology company. The company has explicitly stated that proceeds will support "working capital requirements, general corporate purposes, and the advancement of business objectives." For a clinical-stage company developing cancer immunotherapies, these funds typically support ongoing research and clinical programs.
The offering has two key financial implications for existing shareholders. First, it creates immediate dilution through the issuance of over 3 million new units. Second, the warrants (now trading under symbol BCTXZ) could lead to additional dilution if exercised in the future, though they also represent a potential source of future capital at
The complete exercise of the underwriter's option may suggest reasonable market reception to the offering. ThinkEquity served as the sole book-running manager, and the company utilized an exemption from the TSX Company Manual for interlisted issuers on recognized exchanges like Nasdaq.
PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced underwritten public offering of 3,066,666 units, including 399,999 units sold upon the full exercise of the underwriter’s option to purchase additional units. Each unit consists of one common share (or pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warrants”). Each unit was sold to the public at a price of
The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.
ThinkEquity acted as the sole book-running manager for the offering.
A registration statement on Form S-1 (File No. 333-286670) relating to the securities was filed with the Securities and Exchange Commission (“SEC”) and became effective on April 24, 2025, and a related registration statement was filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended. This offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BriaCell Therapeutics
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Forward Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the Securities and Exchange Commission as well as in the Company's other filings with the Canadian securities regulatory authorities and the Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
FAQ
How much did BriaCell (BCTX) raise in their April 2025 public offering?
What is included in BriaCell's (BCTX) April 2025 public offering units?
When will BCTX warrants start trading on Nasdaq?
How will BriaCell use the proceeds from their $13.8M offering?
What was the exercise price for BriaCell (BCTX) warrants in the April 2025 offering?
